Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHATTIN, AMY MARIE | 2 | 72.9% | +43.5% |
| KOSAR, ANDREW D | 1 | 41.4% | +31.8% |
| SOROUSH, ALI | 1 | 47.3% | +30.3% |
| DAVIS, BRIAN J | 1 | 84.8% | -4.1% |
| HADDAD, MAHER M | 1 | 50.5% | +53.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18396017 | PURINONE DERIVATIVE HYDROCHLORIDE | KOSAR, ANDREW D | — |
| 18566424 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | CHATTIN, AMY MARIE | — |
| 16753159 | BISPECIFIC ANTIBODY | HADDAD, MAHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18396017 | PURINONE DERIVATIVE HYDROCHLORIDE | KOSAR, ANDREW D | — |
| 18566424 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | CHATTIN, AMY MARIE | — |
| 17925934 | AGENT FOR PROTECTING AND/OR REGENERATING NEUROMUSCULAR JUNCTION | SOROUSH, ALI | — |
| 17624502 | A PHARMACEUTICAL COMPOSITION FOR TREATING HEMATOLOGICAL CANCER | CHATTIN, AMY MARIE | — |
| 16753159 | BISPECIFIC ANTIBODY | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1625 | 1 |
| 1643 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18396017 | PURINONE DERIVATIVE HYDROCHLORIDE | KOSAR, ANDREW D | 1625 | §101§112DP | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18566424 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | CHATTIN, AMY MARIE | — | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 17925934 | AGENT FOR PROTECTING AND/OR REGENERATING NEUROMUSCULAR JUNCTION | SOROUSH, ALI | 1614 | §103 | Non-Final OA | — | Pending | Nov 17, 2022 |
| 17624502 | A PHARMACEUTICAL COMPOSITION FOR TREATING HEMATOLOGICAL CANCER | CHATTIN, AMY MARIE | 1643 | §103Other | Non-Final OA | — | Pending | Jan 03, 2022 |
| 16858244 | QUINOLINE DERIVATIVE | DAVIS, BRIAN J | 1614 | Other | Non-Final OA | 18d overdue | Pending | Apr 24, 2020 |
| 16753159 | BISPECIFIC ANTIBODY | HADDAD, MAHER M | 1641 | §103§112 | Final Rejection | — | Pending | Apr 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial